eligibility_summary
Inclusion: adults ≥18 with potentially resectable stage II-III EGFR/ALK-negative NSCLC, measurable disease, ECOG 0-1, adequate organ function, tumor tissue available, controlled HBV/HCV, contraception, consent. Exclusion: metastasis, recent other malignancy, mixed SCLC/NSCLC, recent systemic therapy or chest RT, prior PD-1/PD-L1/CTLA-4 or TROP-2/topoisomerase, pregnancy, hypersensitivity, immunosuppression, major cardiac/pulmonary/autoimmune disease, active HBV/HCV, HIV, transplant, live vaccines, other trials/prohibited meds, refusal of surgery.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 2, single-arm neoadjuvant study in resectable stage II–III EGFR/ALK-negative NSCLC testing: 1) Sacituzumab govitecan—an antibody-drug conjugate (anti–TROP-2 mAb linked to SN-38, a topoisomerase I inhibitor) that delivers cytotoxic SN-38 to TROP-2–expressing tumor cells, causing DNA damage and cell death, 2) Pembrolizumab—a monoclonal antibody checkpoint inhibitor that blocks PD-1 on T cells to restore antitumor immunity. Targets: TROP-2–positive NSCLC cells (ADC internalization) and the PD-1/PD-L1 immune checkpoint on T cells/tumor microenvironment. Neoadjuvant x4 → surgery → pembrolizumab maintenance.